Selecting Candidates for Adjuvant Immunotherapy in cSCC

Panelists emphasize that careful patient selection is essential to optimizing outcomes with adjuvant immunotherapy. Those most likely to benefit include patients with deeply invasive primary tumors, extensive perineural involvement, regional lymph node disease, or positive surgical margins after curative resection. The decision often depends on recurrence risk weighed against comorbidity and immune-related toxicity potential.

They note that multidisciplinary collaboration ensures alignment between surgical, radiation, and medical oncology teams when determining eligibility. Biomarker research, including gene expression profiling and immune signatures, may soon refine these decisions further by predicting response likelihood.

Ultimately, panelists agree that a nuanced understanding of both tumor biology and patient-specific factors guides therapy selection. This precision-driven approach balances efficacy with safety and ensures that adjuvant therapy is reserved for those most likely to derive meaningful benefit.